Based on the fact that TCLlnc1 promoted both tumor growth and the migration of PTCL via TGF-β signaling activation, therapeutic targeting of TGF-β may counteract tumor progression in PTCL with TCLlnc1 overexpression. Here, FTH1P24 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.